FEMY FEMASYS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1339005 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.2%
TTM net income YoY38.7%
TTM EPS YoY175.8%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—
Margins
Gross margin59.9%
Operating margin-929.9%
Net margin-614.7%
FCF margin-877.5%
EBITDA margin-913.3%
Returns
ROE-76.9%
ROA-47.3%
ROIC (approx.)-935.4%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets23.0%
Debt / equity0.00x
Current ratio8.67x
Interest coverage-18.91x
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio19.2%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.29M | $1.63M | $1.07M | $1.21M | $1.18M |
| Cost of revenue | $872,400 | $544,903 | $380,069 | $441,938 | $370,384 |
| Gross profit | $1.42M | $1.08M | $691,901 | $764,280 | $809,305 |
| R&D expense | $7.58M | $8.22M | $7.21M | $5.81M | $4.08M |
| SG&A expense | $6.65M | $6.33M | $6.86M | $5.43M | $4.26M |
| Operating income | -$17.59M | -$17.79M | -$14.51M | -$11.60M | -$8.34M |
| Interest expense | $1.89M | $1.60M | $165,390 | $13,464 | $19,226 |
| Pretax income | -$18.63M | -$18.81M | -$14.24M | -$11.39M | -$7.53M |
| Income tax | $1,297 | $9,602 | $4,338 | $6,300 | $4,000 |
| Net income | -$18.63M | -$18.82M | -$14.25M | -$11.39M | -$7.54M |
| EBITDA | -$17.25M | -$17.49M | -$14.02M | -$11.04M | -$7.75M |
| EPS (basic) | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 |
| EPS (diluted) | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 |
| Weighted avg. shares (diluted) | 39.55M | 22.27M | 15.38M | 11.82M | 6.71M |
| Balance sheet | |||||
| Cash & equivalents | $9.27M | $3.45M | $21.72M | $12.96M | $24.78M |
| Receivables | $616,600 | $488,373 | $98,906 | $77,470 | $84,258 |
| Inventory | $5.74M | $3.05M | $667,118 | $436,723 | $208,270 |
| Current assets | $16.46M | $8.02M | $23.18M | $14.13M | $25.63M |
| PP&E, net | $1.90M | $1.60M | $1.11M | $1.48M | $1.60M |
| Intangibles | $134,914 | $65,918 | $0 | $3,294 | $25,093 |
| Total assets | $20.72M | $12.45M | $27.76M | $16.90M | $28.58M |
| Current liabilities | $3.64M | $8.58M | $3.05M | $1.53M | $1.69M |
| Total liabilities | $14.85M | $10.14M | $9.40M | $1.65M | $2.24M |
| Shareholders' equity | $5.87M | $2.30M | $18.35M | $15.24M | $26.33M |
| Shares outstanding | 2.98M | 23.36M | 21.66M | 11.87M | 11.80M |
| Cash flow statement | |||||
| Operating cash flow | -$18.69M | -$19.44M | -$11.28M | -$10.73M | -$7.93M |
| Capital expenditure | $525,007 | $761,706 | $143,917 | $407,475 | $306,868 |
| Free cash flow | -$19.22M | -$20.21M | -$11.42M | -$11.14M | -$8.24M |
| Investing cash flow | -$630,098 | -$847,764 | -$143,917 | -$407,475 | -$306,868 |
| Financing cash flow | $25.14M | $2.03M | $20.18M | -$681,645 | $29.70M |
| Depreciation & amortization | $342,034 | $297,318 | $483,481 | $561,233 | $591,068 |
| Stock-based compensation | $790,145 | $444,147 | $675,700 | $224,939 | $193,366 |
| Share buybacks | — | $60,753 | $229,953 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.